Oct 10 (Reuters) - Palisade Bio Inc :
* PALISADE BIO CLEARED BY HEALTH CANADA TO COMMENCE PHASE 1 CLINICAL STUDY FOR LEAD PROGRAM, PALI-2108 FOR THE TREATMENT OF ULCERATIVE COLITIS (UC)
* PALISADE BIO INC - ON TRACK COMMENCE SITE INITIATION AND ENROLLMENT FOR STUDY BEFORE YEAR END
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments